Direct oral anticoagulants showed a similar annual rate of thromboembolic events compared to warfarin (0.67% vs 0.83%; HR 0.66; 95% CI 0.22-2.01; p=0.5).
Cohort (n=422)
Yes
Are DOACs as effective and safe as warfarin in preventing thromboembolic events and major bleeding in patients with cardiac amyloidosis and atrial fibrillation?
DOACs and warfarin demonstrate similar efficacy and safety profiles for stroke prevention in patients with cardiac amyloidosis and atrial fibrillation.
Hazard Ratio: 0.66 (95% CI 0.22–2.01)
Absolute Event Rate: 0.67% vs 0.83%
p-value: p=0.5
Background: AF in the setting of cardiac amyloidosis is associated with a high risk of TEs, irrespective of CHA2DS2-VASc score. While warfarin has been the traditional anticoagulant, DOACs offer a promising alternative, but their safety in this population remains underexplored. This study aimed to evaluate the prevalence of thromboembolic events (TEs), including stroke and transient ischemic attack (TIA), and major bleeding events in patients with cardiac amyloidosis (CA) and atrial fibrillation (AF) treated with either warfarin or direct oral anticoagulants (DOACs). Additionally, we aimed to explore whether DOACs are at least as effective as warfarin in protecting against TEs in this population. Methods: This retrospective cohort study analyzed 422 patients with confirmed CA and AF from Mayo Clinic, with a median follow-up of 4.3 years. Data on anticoagulation therapy, baseline characteristics, and outcomes (TEs and bleeding) were collected. Statistical analyses included chi-square tests, t-tests, and Cox regression to assess the relationship between anticoagulation and TE. Results: Among 422 patients, 21 experienced a TE. The annual event rate was 0.83% for warfarin and 0.67% for DOACs, with no significant difference (HR 0.66, CI 0.22–2.01, p = 0.5). Patients with anticoagulation interruptions > 5 days had increased TE risk (HR 3.19, CI 0.97–10.5, p = 0.056). The bleeding rate was 9.9% over 4.3 years (2.33% per year), with no significant differences between anticoagulants. Conclusions: Both warfarin and DOACs have similar, low risks of TEs in CA and AF patients. However, anticoagulation interruptions were associated with increased TE risk, emphasizing the challenges in managing anticoagulation in this population.
Nabi et al. (Thu,) conducted a cohort in Cardiac amyloidosis and atrial fibrillation (n=422). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Thromboembolic events (TEs), including stroke and transient ischemic attack (TIA) (HR 0.66, 95% CI 0.22-2.01, p=0.5). Direct oral anticoagulants showed a similar annual rate of thromboembolic events compared to warfarin (0.67% vs 0.83%; HR 0.66; 95% CI 0.22-2.01; p=0.5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: